Clinical Commander

Back to dossier
cardio.hypertensive-emergency.clonidine-withdrawal.v1PRODUCTION
cardio.hypertensive-emergency.clonidine-withdrawal.v1

Clonidine / α2-agonist withdrawal hypertensive crisis (rebound NE surge HTN + tachy + diaphoresis + tremor 18-72 h after abrupt cessation of clonidine, methyldopa, dexmedetomidine, or guanfacine)

cardiologyacuteadult
Hard-required inputs
0 / 12
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Clonidine withdrawal crisis = abrupt cessation of central α2-agonist → rebound NE release surge from removal of presynaptic α2-mediated inhibition → severe HTN + tachy + diaphoresis + tremor + agitation 18-72 h after last dose. Pharmacology pivot: RESUME CLONIDINE (oral 0.1-0.3 mg load + transdermal Catapres-TTS-3 patch 0.3 mg/24h max for sustained); IV labetalol bridge (mixed α/β SAFE here because resumed α2-agonist restores central inhibition — different from pure cocaine pharmacology); phentolamine IV for severe. AVOID isolated β-blocker (unopposed alpha — same principle as cocaine + pheo). Route to parent engine for shared HTN-emergency arc; this dossier owns the rebound-specific pharmacology + perioperative + adherence prevention.

Inputs
5
Actions
0
Advance rule
Set
Advance when

clonidine withdrawal etiology confirmed by history (med + cessation timing 18-72 h)

Patient inputs (12)

Older patients on clonidine for resistant HTN or perioperative use overrepresented; cognitive impairment increases adherence-failure risk

Confirms etiology — clonidine PO (oral 0.1-0.3 mg BID-TID + dose level), transdermal Catapres-TTS-1/2/3 (0.1/0.2/0.3 mg/24h), methyldopa, dexmedetomidine infusion (often ICU), guanfacine, tizanidine high-dose; concurrent β-blocker therapy elevates risk

Confirms timing of last dose + reason for cessation (NPO for OR, ran out of refill, deliberate stop, transdermal patch failure); guides resumption strategy + future taper plan

Classic rebound features — fine tremor + agitation + insomnia + occipital headache distinguish from primary HTN urgency

Demand ischemia from severe HTN + tachycardia; QTc baseline; arrhythmia screen

NE surge demand ischemia rule-out (Type 2 MI in elderly with CAD)

eGFR drives drug dosing for resumed clonidine + IV labetalol; baseline for renal injury assessment (clonidine dose-reduction in CKD)

Focal deficit suggests ICH (severe rebound HTN can cause ICH in elderly); exclude with CT head if neuro deficit

Defines crisis threshold; drives titration of resumed clonidine + IV labetalol; rebound HTN can be more severe than baseline pre-clonidine BP

Component of MAP; DBP >120 supports crisis criterion + rebound severity

Rebound tachycardia from NE surge; HR often 100-140 even at rest; risk of demand ischemia in elderly with CAD

Hyperthermia uncommon in clonidine withdrawal but possible; differentiates from sympathomimetic toxidrome

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationalseverepost_op_missed_clonidine_dose_during_NPO
    Patient on clonidine for chronic HTN underwent surgery with NPO status + clonidine held → severe rebound HTN crisis 18-72 h post-op (preventable)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretransdermal_patch_failure
    Clonidine transdermal patch detached, removed, or expired without replacement → withdrawal crisis 24-72 h after patch loss (depot effect delays onset)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_clonidine_withdrawal_events
    Patient with multiple prior clonidine withdrawal crises despite counseling — suggests systemic adherence failure (cognitive, financial, psychiatric, substance use) requiring multidisciplinary intervention
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereconcurrent_beta_blocker_worsening_clonidine_rebound
    Patient on concurrent β-blocker therapy → clonidine withdrawal triggers severe HTN with worsened severity due to unopposed alpha vasoconstriction (β-blocker leaves alpha-vasoconstriction unopposed when clonidine no longer suppressing NE)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

Clonidine / α2-agonist withdrawal HTN crisis — RESUME CLONIDINE first (PO + transdermal patch for sustained), IV labetalol bridge, phentolamine for severe, AVOID isolated β-blocker, perioperative protocol + adherence counseling for prevention
axis: clonidine_withdrawal_htn_crisis_pharmacology
Selected axis "Clonidine / α2-agonist withdrawal HTN crisis — RESUME CLONIDINE first (PO + transdermal patch for sustained), IV labetalol bridge, phentolamine for severe, AVOID isolated β-blocker, perioperative protocol + adherence counseling for prevention" by default fallback (first axis)
  • clonidine
    first line
    central_alpha2_agonist
    0.1-0.3 mg PO loading dose, then 0.1-0.2 mg PO q6-8h titrate (or restart home dose); transdermal Catapres-TTS-3 patch 0.3 mg/24h × 7 d MAX • PO + transdermal • q6-8h PO + weekly patch
    triggers: clonidine_withdrawal_confirmed_or_suspected
    Reid Lancet 1986 PMID 2867300 — resumption of α2-agonist restores central inhibition + reverses rebound NE surge; transdermal patch provides sustained release (2-3 d onset due to depot effect, bridge with PO)
    rxcui 2599
  • labetalol
    second line
    mixed_alpha_beta_blocker
    10-20 mg IV q10 min titrate to SBP <160 (max 300 mg cumulative), OR infusion 0.5-2 mg/min • IV • PRN bolus or continuous
    triggers: persistent_HTN_after_clonidine_resumption
    Mixed α/β safe in clonidine withdrawal (different from cocaine — resumed α2-agonist restores central inhibition so β-blockade does not produce same unopposed-alpha problem); standard HTN-emergency agent per AHA 2025
    rxcui 6185
  • phentolamine
    second line
    alpha_adrenergic_blocker
    1-5 mg IV q5-15 min titrate • IV • PRN bolus
    triggers: severe_rebound_HTN_failed_clonidine_and_labetalol, concurrent_beta_blocker_unopposed_alpha_rescue
    Pure alpha-blocker reverses rebound NE-driven alpha-vasoconstriction; rescue if concurrent β-blocker therapy worsens rebound
    rxcui 8153
  • nitroglycerin
    second line
    organic_nitrate
    5-200 mcg/min IV titrate q3-5 min • IV • continuous
    triggers: persistent_HTN_with_chest_pain_or_pulmonary_edema
    Vasodilator + coronary vasodilator; useful if pulmonary edema from acute LV strain
    rxcui 4917
  • lorazepam
    add on
    benzodiazepine
    0.5-1 mg IV q4-6h PRN • IV • PRN
    triggers: symptomatic_tremor_agitation_insomnia
    Symptomatic relief of rebound features (tremor + agitation + insomnia); not the primary anti-HTN agent here
    rxcui 6470
  • methyldopa
    comorbidity specific
    central_alpha2_agonist_alternative
    250-500 mg PO BID-TID • PO • BID-TID
    triggers: clonidine_unavailable_or_intolerant, pregnancy_HTN_co_management
    Alternative central α2-agonist if clonidine unavailable; preferred in pregnancy (long safety record)
    rxcui 6876
  • AVOID isolated β-blocker without α-blockade or clonidine resumption
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: clonidine_withdrawal_confirmed
    Same unopposed-alpha pharmacological principle as cocaine + pheochromocytoma — isolated β-blockade leaves alpha-vasoconstriction unopposed → worsens HTN; mixed α/β labetalol is safe here because clonidine resumption restores central inhibition
  • GRADUAL TAPER over 7-14 d if discontinuing clonidine
    add on
    prevention_protocol
    0.3 mg → 0.2 mg × 3 d → 0.1 mg × 3 d → 0.05 mg × 3 d → off • PO • graduated reduction
    triggers: planned_discontinuation_of_clonidine
    Reid Lancet 1986 PMID 2867300 — taper over 7-14 d minimizes rebound risk; consider introducing alternative HTN regimen (ACEi/ARB + CCB) before taper to maintain BP control
  • PERIOPERATIVE PROTOCOL — continue clonidine peri-op or convert to transdermal patch 24-48 h pre-op
    add on
    prevention_protocol
    Catapres-TTS-3 patch 0.3 mg/24h placed 24-48 h pre-op • transdermal • weekly
    triggers: scheduled_OR_with_NPO_status
    Garbus Anesthesiology 1979 — transdermal patch maintains drug levels during NPO + surgery; preventing perioperative withdrawal crisis

outpatient playbook — drug actions (3)

  1. 1. continue clonidine regimen long-term if indicated
    rxcui 2599
    Home dose • PO + transdermal • BID-TID + weekly
    trigger: Stable maintenance
    Sustained adherence — clonidine for resistant HTN per ACC/AHA 2025
  2. 2. alternative regimen if successfully tapered off clonidine
    rxcui 17767
    Amlodipine 5-10 ± lisinopril ± chlorthalidone ± β-blocker • PO • daily
    trigger: Off clonidine
    ACC/AHA 2025 4-tier ladder
  3. 3. methyldopa alternative if pregnancy
    rxcui 7396
    250-500 mg PO BID-TID • PO • BID-TID
    trigger: Pregnancy + HTN
    Methyldopa preferred α2-agonist alternative in pregnancy

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Abrupt cessation (or major dose reduction) of clonidine, methyldopa, dexmedetomidine, guanfacine, or tizanidine within last 18-72 h + SBP ≥180 / DBP ≥120 (Reid Lancet 1986 PMID 2867300); HTN + tachycardia + diaphoresis + tremor + agitation + headache + insomnia 18-72 h after missed clonidine doses — classic rebound syndrome (Hansson 1980; Reid 1986); Clonidine transdermal patch failure (detached, removed, expired without replacement) — depot effect delays withdrawal onset to 24-72 h after patch loss.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Clonidine / α2-agonist withdrawal hypertensive crisis (rebound NE surge HTN + tachy + diaphoresis + tremor 18-72 h after abrupt cessation of clonidine, methyldopa, dexmedetomidine, or guanfacine)** (cardio.hypertensive-emergency.clonidine-withdrawal.v1).
Scope: Clonidine withdrawal crisis = abrupt cessation of central α2-agonist → rebound NE release surge from removal of presynaptic α2-mediated inhibition → severe HTN + tachy + diaphoresis + tremor + agitation 18-72 h after last dose. Pharmacology pivot: RESUME CLONIDINE (oral 0.1-0.3 mg load + transdermal Catapres-TTS-3 patch 0.3 mg/24h max for sustained); IV labetalol bridge (mixed α/β SAFE here because resumed α2-agonist restores central inhibition — different from pure cocaine pharmacology); phentolamine IV for severe. AVOID isolated β-blocker (unopposed alpha — same principle as cocaine + pheo). Route to parent engine for shared HTN-emergency arc; this dossier owns the rebound-specific pharmacology + perioperative + adherence prevention.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Clonidine / α2-agonist withdrawal HTN crisis — RESUME CLONIDINE first (PO + transdermal patch for sustained), IV labetalol bridge, phentolamine for severe, AVOID isolated β-blocker, perioperative protocol + adherence counseling for prevention**.
1. clonidine 0.1-0.3 mg PO loading dose, then 0.1-0.2 mg PO q6-8h titrate (or restart home dose); transdermal Catapres-TTS-3 patch 0.3 mg/24h × 7 d MAX PO + transdermal q6-8h PO + weekly patch (central_alpha2_agonist, first line) — Reid Lancet 1986 PMID 2867300 — resumption of α2-agonist restores central inhibition + reverses rebound NE surge; transdermal patch provides sustained release (2-3 d onset due to depot effect, bridge with PO)
2. labetalol 10-20 mg IV q10 min titrate to SBP <160 (max 300 mg cumulative), OR infusion 0.5-2 mg/min IV PRN bolus or continuous (mixed_alpha_beta_blocker, second line) — Mixed α/β safe in clonidine withdrawal (different from cocaine — resumed α2-agonist restores central inhibition so β-blockade does not produce same unopposed-alpha problem); standard HTN-emergency agent per AHA 2025
3. phentolamine 1-5 mg IV q5-15 min titrate IV PRN bolus (alpha_adrenergic_blocker, second line) — Pure alpha-blocker reverses rebound NE-driven alpha-vasoconstriction; rescue if concurrent β-blocker therapy worsens rebound
4. nitroglycerin 5-200 mcg/min IV titrate q3-5 min IV continuous (organic_nitrate, second line) — Vasodilator + coronary vasodilator; useful if pulmonary edema from acute LV strain
5. lorazepam 0.5-1 mg IV q4-6h PRN IV PRN (benzodiazepine, add on) — Symptomatic relief of rebound features (tremor + agitation + insomnia); not the primary anti-HTN agent here
6. methyldopa 250-500 mg PO BID-TID PO BID-TID (central_alpha2_agonist_alternative, comorbidity specific) — Alternative central α2-agonist if clonidine unavailable; preferred in pregnancy (long safety record)
7. AVOID isolated β-blocker without α-blockade or clonidine resumption AVOID N/A N/A (do_not_use, contraindication substitute) — Same unopposed-alpha pharmacological principle as cocaine + pheochromocytoma — isolated β-blockade leaves alpha-vasoconstriction unopposed → worsens HTN; mixed α/β labetalol is safe here because clonidine resumption restores central inhibition
8. GRADUAL TAPER over 7-14 d if discontinuing clonidine 0.3 mg → 0.2 mg × 3 d → 0.1 mg × 3 d → 0.05 mg × 3 d → off PO graduated reduction (prevention_protocol, add on) — Reid Lancet 1986 PMID 2867300 — taper over 7-14 d minimizes rebound risk; consider introducing alternative HTN regimen (ACEi/ARB + CCB) before taper to maintain BP control
9. PERIOPERATIVE PROTOCOL — continue clonidine peri-op or convert to transdermal patch 24-48 h pre-op Catapres-TTS-3 patch 0.3 mg/24h placed 24-48 h pre-op transdermal weekly (prevention_protocol, add on) — Garbus Anesthesiology 1979 — transdermal patch maintains drug levels during NPO + surgery; preventing perioperative withdrawal crisis

Setting playbook (outpatient) — Long-term PCP + cardiology coordination — sustained adherence, BP <130/80, no recurrent withdrawal events, medication-card + MedicAlert maintained, perioperative protocol invoked for any future surgery
10. continue clonidine regimen long-term if indicated Home dose PO + transdermal BID-TID + weekly — Stable maintenance (Sustained adherence — clonidine for resistant HTN per ACC/AHA 2025)
11. alternative regimen if successfully tapered off clonidine Amlodipine 5-10 ± lisinopril ± chlorthalidone ± β-blocker PO daily — Off clonidine (ACC/AHA 2025 4-tier ladder)
12. methyldopa alternative if pregnancy 250-500 mg PO BID-TID PO BID-TID — Pregnancy + HTN (Methyldopa preferred α2-agonist alternative in pregnancy)

Non-pharmacologic actions:
- 90-day fill auto-refill confirmed annually
- Medication card in wallet
- MedicAlert bracelet active
- Perioperative protocol templated in chart for any planned surgery

AVOID / contraindication checks:
- Isolated_beta_blocker_avoid_in_clonidine_withdrawal_use_labetalol_or_resume_clonidine_first (Reid Lancet 1986 PMID 2867300; AHA 2025 HTN)
- Concurrent_beta_blocker_worsens_clonidine_rebound (taper β blocker before clonidine if both being discontinued)
- Gradual_taper_over_7 14d_when_discontinuing_clonidine (Reid 1986)
- Perioperative_continuation_or_transdermal_conversion_for_NPO_OR (Garbus Anesthesiology 1979)
- Transdermal_patch_max_dose_0.3mg_per_24h (Catapres TTS 3 manufacturer)
- Reduce_clonidine_dose_in_CKD_eGFR_below_30 (renal excretion ~50%)
- Resume_clonidine_first_then_labetalol_then_phentolamine (sequenced approach)

Monitoring

Regimen monitoring:
- continuous ECG q15min BP minimum 24h (AHA 2025 HTN)
- serial troponin q3-6h x2 if chest pain or elderly CAD
- serial ECG q4h x12-24h
- tremor and agitation assessment q1h
- transdermal patch onset takes 2-3 days due to depot effect bridge with PO
- taper plan documentation for future discontinuation
- medication card and MedicAlert for recurrent events
- perioperative protocol documentation in chart

Setting (outpatient) monitoring:
- Quarterly BP
- Annual ECG + lipid + A1c
- Annual medication review + adherence verification

Follow-up plan: CRITICAL ADHERENCE COUNSELING + medication-card warning ("Do not stop clonidine abruptly — taper over 7-14 d if discontinuing"); MEDICALERT BRACELET if recurrent events; if patient continues clonidine — establish reliable refill system + advance-supply (90-day fill); if patient discontinuing clonidine — gradual taper over 7-14 d (e.g., 0.3 mg → 0.2 mg × 3 d → 0.1 mg × 3 d → 0.05 mg × 3 d → off); PERIOPERATIVE PROTOCOL — continue clonidine perioperatively OR convert to transdermal Catapres-TTS-3 patch 24-48 h pre-op (Garbus Anesthesiology 1979); transition to alternative HTN regimen with appropriate titration if discontinuing (e.g., introduce ACEi/ARB + CCB before clonidine taper); psychiatric/substance use evaluation if recurrent events suggest deeper issue; PCP + cardiology follow-up within 1-2 weeks
- Close-out criterion: taper plan documented OR continuation supply secured + medication-card issued + perioperative protocol noted + 1-2 wk follow-up booked

Monitoring phase: Continuous ECG + telemetry; q15-30 min BP; serial troponin q3-6h × 2 if elderly or CAD; serial neuro exam q2h × 12 h; tremor + agitation assessment; UOP

Disposition

Current setting: outpatient — Long-term PCP + cardiology coordination — sustained adherence, BP <130/80, no recurrent withdrawal events, medication-card + MedicAlert maintained, perioperative protocol invoked for any future surgery

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + cardio.htn.resistant.v1 for chronic management

Escalation triggers (move to higher acuity):
- Recurrent withdrawal events → addiction medicine + multidisciplinary intervention
- BP rebound → urgent visit

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] Patient on clonidine for chronic HTN underwent surgery with NPO status + clonidine held → severe rebound HTN crisis 18-72 h post-op (preventable)
- [SEVERE] Clonidine transdermal patch detached, removed, or expired without replacement → withdrawal crisis 24-72 h after patch loss (depot effect delays onset)
- [SEVERE] Patient with multiple prior clonidine withdrawal crises despite counseling — suggests systemic adherence failure (cognitive, financial, psychiatric, substance use) requiring multidisciplinary intervention

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + Reid Lancet 1986 PMID 2867300 (clonidine withdrawal syndrome comprehensive review) + Garbus Anesthesiology 1979 (perioperative protocol) [PMID:2867300](https://pubmed.ncbi.nlm.nih.gov/2867300/)
- Cited evidence (PMID 7282543) [PMID:7282543](https://pubmed.ncbi.nlm.nih.gov/7282543/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 10972386) [PMID:10972386](https://pubmed.ncbi.nlm.nih.gov/10972386/)
- Cited evidence (PMID 18391116) [PMID:18391116](https://pubmed.ncbi.nlm.nih.gov/18391116/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2025 ACC/AHA HTN Guideline (Whelton) + Reid Lancet 1986 PMID 2867300 (clonidine withdrawal syndrome comprehensive review) + Garbus Anesthesiology 1979 (perioperative protocol) — PMID:2867300
  • Cited evidence (PMID 7282543) — PMID:7282543
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 10972386) — PMID:10972386
  • Cited evidence (PMID 18391116) — PMID:18391116